Huang Y - Search Results

1

[Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer.].

Huang Y, Yang J, Huang Y, Xu C, Zhou Q, Wang Z, Wu Y. Huang Y, et al. Zhongguo Fei Ai Za Zhi. 2009 May 20;12(5):412-6. doi: 10.3779/j.issn.1009-3419.2009.05.019. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20719136 Free article. Chinese.

2

Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial.

Huang YJ, Wu YL, Xie SX, Yang JJ, Huang YS, Liao RQ. Huang YJ, et al. Chin Med J (Engl). 2007 Mar 20;120(6):458-62. Chin Med J (Engl). 2007. PMID: 17439736 Clinical Trial.

3

[Gefitinib target treatment in non-small cell lung cancer].

Wu YL, Yang JJ, Lin JY, Huang YJ, Liao RQ, Huang YS, Zhou Q, Xu CR, Wang Z. Wu YL, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):98-102. Zhonghua Jie He He Hu Xi Za Zhi. 2007. PMID: 17445469 Clinical Trial. Chinese.

4

Three cases of severe hepatic impairment caused by erlotinib.

Huang YS, An SJ, Chen ZH, Wu YL. Huang YS, et al. Br J Clin Pharmacol. 2009 Sep;68(3):464-7. doi: 10.1111/j.1365-2125.2009.03459.x. Br J Clin Pharmacol. 2009. PMID: 19740406 Free PMC article. No abstract available.

5

[The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer.].

Huang Y, Yang J, Yang Y, Huang Y, Liao R, Wu Y. Huang Y, et al. Zhongguo Fei Ai Za Zhi. 2009 Dec 20;12(12):1266-70. doi: 10.3779/j.issn.1009-3419.2009.12.08. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20723381 Free article. Chinese.

6

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy.

An SJ, Huang YS, Chen ZH, Su J, Yang Y, Chen JG, Yan HH, Lin QX, Yang JJ, Yang XN, Zhou Q, Zhang XC, Wu YL. An SJ, et al. Among authors: huang ys. Med Oncol. 2012 Jun;29(2):627-32. doi: 10.1007/s12032-011-9924-x. Epub 2011 Apr 3. Med Oncol. 2012. PMID: 21461966

7

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL. Zhou Q, et al. J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788562

8

Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.

Huang YS, Yang JJ, Zhang XC, Yang XN, Huang YJ, Xu CR, Zhou Q, Wang Z, Su J, Wu YL. Huang YS, et al. Chin Med J (Engl). 2011 Aug;124(16):2457-60. Chin Med J (Engl). 2011. PMID: 21933587

9

Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib.

Huang YS, Huang B, Wu YL. Huang YS, et al. Chin Med J (Engl). 2011 Nov;124(22):3834-7. Chin Med J (Engl). 2011. PMID: 22340252

10

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, Wang Z, Xu CR, Huang YS, Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Jiang BY, Dong S, Wu YL. Yang JJ, et al. Lung Cancer. 2013 Jan;79(1):33-9. doi: 10.1016/j.lungcan.2012.09.016. Epub 2012 Oct 15. Lung Cancer. 2013. PMID: 23079155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81,559 results

Search Page

Filters